BVD-523

DRUG4 trials

Conditions

Acute Myelogenous LeukemiaAdvanced Solid TumorsCancer of PancreasCancer of the PancreasMyelodysplastic SyndromePancreas CancerPancreatic CancerUveal Melanoma

Phase 1

Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies

CompletedNCT01781429

BioMed Valley Discoveries, IncAdvanced Solid Tumors

Start: 2013-03-31End: 2018-09-30Updated: 2020-03-20

Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes

CompletedNCT02296242

BioMed Valley Discoveries, IncAcute Myelogenous Leukemia, Myelodysplastic Syndrome

Start: 2014-11-30End: 2017-06-15Updated: 2019-01-29

BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer

TerminatedNCT02608229

Washington University School of MedicineCancer of Pancreas, Cancer of the Pancreas, Pancreas Cancer +1

Start: 2016-06-06End: 2020-05-21Updated: 2021-04-21

Phase 2

A Phase II Study of BVD-523 in Metastatic Uveal Melanoma

TerminatedNCT03417739

Dana-Farber Cancer InstituteUveal Melanoma

Start: 2018-03-26End: 2025-07-16Updated: 2026-07-27

The Oncologist2022-11-2534 citations

Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers.

2021-01-0323 citations

A phase II study of ERK inhibition by ulixertinib (BVD-523) in metastatic uveal melanoma.

Journal of Clinical Oncology2020-05-2016 citations

Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval in patients with advanced solid tumor malignancies

Cancer Chemotherapy and Pharmacology2018-03-3024 citations

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study

Cancer Discovery2017-12-15401 citations

Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)

Molecular Cancer Therapeutics2017-09-22225 citations

Abstract CT003: Activity of the ERK1/2 inhibitor ulixertinib (BVD-523) in patients with <i>BRAF</i> and <i>NRAS</i> mutant melanoma

Cancer Research2017-07-011 citations

First-in-class oral ERK1/2 inhibitor Ulixertinib (BVD-523) in patients with advanced solid tumors: Final results of a phase I dose escalation and expansion study.

Journal of Clinical Oncology2017-05-2015 citations

Abstract 4693: The selective ERK inhibitor BVD-523 is active in models of MAPK pathway-dependent cancers, including those with intrinsic and acquired drug resistance

Cancer Research2015-08-0121 citations

Dose escalation stage of a first-in-class phase I study of the novel oral ERK 1/2 kinase inhibitor BVD-523 (ulixertinib) in patients with advanced solid tumors.

Journal of Clinical Oncology2015-05-2015 citations

BVD-523

Sponsors

Conditions

Phase 1

Phase 2

Related Papers